---
title: Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase
  inhibition and CAR T-cell therapy
date: '2024-10-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39374522/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241007200551&v=2.18.0.post9+e462414
source: Blood
description: Chimeric antigen receptor (CAR) T-cells and bispecific antibodies (BsAb)
  targeting B-cell maturation antigen (BCMA) have significantly advanced the treatment
  of relapsed and refractory multiple myeloma (MM). Resistance to BCMA-targeting therapies,
  nonetheless, remains a significant challenge. BCMA shedding by gamma-secretase is
  a known resistance mechanism, and preclinical studies suggest that inhibition may
  improve anti-BCMA therapy. Leveraging a phase I clinical trial of the ...
disable_comments: true
---
Chimeric antigen receptor (CAR) T-cells and bispecific antibodies (BsAb) targeting B-cell maturation antigen (BCMA) have significantly advanced the treatment of relapsed and refractory multiple myeloma (MM). Resistance to BCMA-targeting therapies, nonetheless, remains a significant challenge. BCMA shedding by gamma-secretase is a known resistance mechanism, and preclinical studies suggest that inhibition may improve anti-BCMA therapy. Leveraging a phase I clinical trial of the ...